RLMD קפיטליזציה חשבונאית Relmada Therapeutics, Inc.

The fate of Relmada Therapeutics (RLMD) is directly tied to the success of its R&D projects and capital expenditure efficiency, as stable income is currently absent and the indicator stands at 0.21. The business relies on the development of cutting-edge therapies for psychiatric disorders and CNS pathologies. This price chart reflects the quotes of an asset whose risks are mitigated by testing NMDA receptor antagonists across various treatment regimens.

To select high-quality assets, an investor must rely on the actual net asset value, excluding market noise. The current 0.21 metric reflects the actual capital of Relmada Therapeutics (RLMD), which is critical for assessing financial stability during the development of the REL-1017 drug, while the volatility of book capitalization allows for the timely identification of false growth impulses within the biopharmaceutical sector.